{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-032080","form_type":"8-K","ticker":"RNAC","cik":"0001453687","company_name":"Cartesian Therapeutics, Inc.","filed_at":"2024-07-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.105900+00:00","generated_at":"2026-05-31T23:44:59.532185+00:00","sec_items":["1.01","5.03","3.02","5.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Cartesian raises $130M via PIPE; Phase 2b MG trial meets primary endpoint, 71% responder rate","bullets":["Raised ~$130M by selling 3.56M common shares and 2.94M Series B convertible preferred shares at $20 each.","Phase 2b trial of Descartes-08 in myasthenia gravis met primary endpoint: 71% of treated patients had ≥5-point MGC improvement vs 25% placebo (p=0.018).","Descartes-08 well tolerated with no cytokine release syndrome or neurotoxicity; supports outpatient administration without preconditioning chemo.","Appointed Kemal Malik, MBBS to Board; first patient dosed in Phase 2 SLE trial of Descartes-08."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-032080","json":"https://secwatch.observer/filing/0001140361-24-032080.json","markdown":"https://secwatch.observer/filing/0001140361-24-032080.md","text":"https://secwatch.observer/filing/0001140361-24-032080.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1453687/000114036124032080/0001140361-24-032080-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1453687/000114036124032080/ef20031962_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T23:44:59.532185+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bbc178a7c4","claim":"Kemal Malik was appointed as Class II director at Cartesian Therapeutics, Inc..","evidence_excerpt":"On July 1, 2024, the Board of Directors (the “Board”) of the Company appointed Kemal Malik, MBBS as a Class II director, and fixed the size of the Board at nine directors.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1453687/000114036124032080/0001140361-24-032080-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class II director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}